Technical Analysis for BLUE - bluebird bio, Inc.

Grade Last Price % Change Price Change
F 25.71 -1.12% -0.29
BLUE closed down 1.12 percent on Thursday, July 29, 2021, on 35 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Aug 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical BLUE trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -1.12%
Pocket Pivot Bullish Swing Setup -1.12%
Wide Bands Range Expansion -1.12%
Oversold Stochastic Weakness -1.12%
NR7 Range Contraction -0.81%
Doji - Bullish? Reversal -0.81%
Oversold Stochastic Weakness -0.81%
Older End-of-Day Signals for BLUE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Slingshot Bearish Entry about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
Possible Inside Day about 4 hours ago
Down 1% about 5 hours ago
60 Minute Opening Range Breakdown about 7 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


bluebird bio, Inc. Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Medical Genetics Dystrophy Summit Childhood Human Disease Human Diseases Sickle Cell Disease Genetic Genealogy Thalassemia Iglo Blood Disorder Leukodystrophy Oncology Diseases

Is BLUE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 68.39
52 Week Low 24.24
Average Volume 1,203,911
200-Day Moving Average 37.47
50-Day Moving Average 30.45
20-Day Moving Average 28.29
10-Day Moving Average 26.50
Average True Range 1.13
ADX 34.06
+DI 13.00
-DI 29.03
Chandelier Exit (Long, 3 ATRs) 29.29
Chandelier Exit (Short, 3 ATRs) 28.76
Upper Bollinger Bands 32.56
Lower Bollinger Band 24.03
Percent B (%b) 0.2
BandWidth 30.13
MACD Line -1.44
MACD Signal Line -1.26
MACD Histogram -0.1858
Fundamentals Value
Market Cap 1.7 Billion
Num Shares 66.2 Million
EPS -12.00
Price-to-Earnings (P/E) Ratio -2.14
Price-to-Sales 10.47
Price-to-Book 1.92
PEG Ratio 0.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.26
Resistance 3 (R3) 27.40 27.02 27.00
Resistance 2 (R2) 27.02 26.63 26.95 26.91
Resistance 1 (R1) 26.37 26.39 26.18 26.23 26.83
Pivot Point 25.99 25.99 25.90 25.92 25.99
Support 1 (S1) 25.34 25.60 25.15 25.20 24.59
Support 2 (S2) 24.96 25.36 24.89 24.51
Support 3 (S3) 24.31 24.96 24.42
Support 4 (S4) 24.17